Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Colorcon
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Last Updated: September 30, 2022

FOLLISTIM AQ Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Tradename: FOLLISTIM AQ
Recent Clinical Trials for FOLLISTIM AQ

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Ferring PharmaceuticalsPhase 2
Center for Human ReproductionPhase 1/Phase 2
Michigan Reproductive MedicinePhase 4

See all FOLLISTIM AQ clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FOLLISTIM AQ Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FOLLISTIM AQ Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. FOLLISTIM AQ follitropin beta Injection 021273 See Plans and Pricing 2017-01-15 Company disclosures
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 See Plans and Pricing 2015-06-16 Company disclosures
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 See Plans and Pricing 2017-01-15 Company disclosures
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 See Plans and Pricing 2018-07-23 Company disclosures
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc. FOLLISTIM AQ CARTRIDGE follitropin beta Injection 021211 See Plans and Pricing 2018-07-23 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for FOLLISTIM AQ Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for FOLLISTIM AQ

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122010000011 Germany See Plans and Pricing FORMER OWNER: MERCK SHARP & DOHME B.V., 2031 BN HAARLEM, NL
96C0010 Belgium See Plans and Pricing PRODUCT NAME: HORMONE FOLLICO-STIMULANTE, HUMAINE RECOMBINANTE; NAT. REGISTRATION NO/DATE: D 13156 19951020; FIRST REGISTRATION: FI - 713/845/94 19940815
SPC/GB10/022 United Kingdom See Plans and Pricing PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTERED: UK EU/1/09/609/001 20100125; UK EU/1/09/609/002 20100125
6/2010 Austria See Plans and Pricing PRODUCT NAME: CORIFOLLITROPIN ALFA; REGISTRATION NO/DATE: EU/1/09/609/001-002 20100125
2001C/020 Belgium See Plans and Pricing PRODUCT NAME: LUTROPINE ALFA; REGISTRATION NO/DATE: EU/1/00/155/001 20001129
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Medtronic
Johnson and Johnson
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.